Published in BMC Dermatol on November 12, 2009
Alopecia areata update. J Am Acad Dermatol (2000) 2.83
Guidelines for the management of alopecia areata. Br J Dermatol (2003) 2.41
Interventions for alopecia areata. Cochrane Database Syst Rev (2008) 1.55
Children with alopecia areata: psychiatric symptomatology and life events. J Am Acad Child Adolesc Psychiatry (1997) 1.31
Alopecia in the United States: outpatient utilization and common prescribing patterns. J Am Acad Dermatol (2007) 1.08
Alopecia areata in children. Cutis (2008) 1.03
Management of hair loss. Dermatol Clin (2005) 1.02
Alopecia areata: treatment of today and tomorrow. J Investig Dermatol Symp Proc (2003) 1.00
Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol (2003) 0.98
Alopecia areata: what to expect from current treatments. Cleve Clin J Med (2005) 0.81
What's missing from this picture? An approach to alopecia in children. Arch Dis Child Educ Pract Ed (2007) 0.80
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol (2007) 4.61
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature (2010) 2.85
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol (2010) 2.33
Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol (2002) 2.26
Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood (2002) 2.20
Acrodermatitis enteropathica-like eruption and failure to thrive as presenting signs of cystic fibrosis. J Am Acad Dermatol (2006) 2.05
Specialty bashing during medical training: experiences of students applying to a dermatology residency program. J Am Acad Dermatol (2012) 2.01
Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial. Pediatr Dermatol (2012) 2.00
History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol (2009) 1.96
Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr (2007) 1.76
Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol (2011) 1.75
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol (2005) 1.71
Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci (2011) 1.67
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood (2004) 1.60
Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood (2007) 1.59
Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome. Blood (2004) 1.58
Success in the dermatology resident match in 2003: perceptions and importance of home institutions and away rotations. Arch Dermatol (2006) 1.57
Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet (2007) 1.55
p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol (2003) 1.54
Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch Dermatol (2002) 1.54
Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol (2002) 1.54
Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. J Am Acad Dermatol (2004) 1.53
Characterization of Staphylococcus aureus cutaneous infections in a pediatric dermatology tertiary health care outpatient facility. J Am Acad Dermatol (2010) 1.50
Cigarette smoking, stress-induced analgesia and pain perception in men and women. Pain (2005) 1.47
Computer-assisted instruction versus traditional lecture for medical student teaching of dermatology morphology: a randomized control trial. J Am Acad Dermatol (2008) 1.44
Effect of a vascular endothelial cadherin antagonist in a rat lung transplant model. Ann Thorac Surg (2013) 1.43
Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst (2003) 1.42
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Mycosis fungoides with tinea pseudoimbricata owing to Trichophyton rubrum infection. J Cutan Med Surg (2007) 1.39
Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res (2012) 1.39
Medical and dermatology dictionaries: an examination of unstructured definitions and a proposal for the future. J Am Acad Dermatol (2004) 1.38
Cutaneous manifestations of Hodgkin's disease. Int J Dermatol (2006) 1.36
Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther (2005) 1.35
Up-regulation of Flotillin-2 is associated with melanoma progression and modulates expression of the thrombin receptor protease activated receptor 1. Cancer Res (2004) 1.33
Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol (2010) 1.29
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc Natl Acad Sci U S A (2010) 1.26
Skin cancer detection by spectroscopic oblique-incidence reflectometry: classification and physiological origins. Appl Opt (2004) 1.22
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat (2008) 1.22
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol (2010) 1.20
Eruptive post-chemotherapy in situ melanomas and dysplastic nevi. Pediatr Dermatol (2007) 1.19
Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol (2009) 1.18
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood (2012) 1.15
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides. J Am Acad Dermatol (2008) 1.12
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol (2006) 1.12
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol (2014) 1.11
Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood (2002) 1.10
Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res (2002) 1.10
Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol (2012) 1.09
Characteristics and behaviors associated with HIV infection among inmates in the North Carolina prison system. Am J Public Health (2009) 1.09
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis (2006) 1.09
Skin lesions associated with Fusarium infection. J Am Acad Dermatol (2002) 1.09
Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood (2005) 1.09
Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer (2010) 1.07
Haplotype and genotypes of the VDR gene and cutaneous melanoma risk in non-Hispanic whites in Texas: a case-control study. Int J Cancer (2008) 1.06
Growth failure in early life: an important manifestation of Turner syndrome. Horm Res (2002) 1.06
A method for fitting regression splines with varying polynomial order in the linear mixed model. Stat Med (2006) 1.05
An evaluation of HIV testing among inmates in the North Carolina prison system. Am J Public Health (2009) 1.05
Viral-associated trichodysplasia of immunosuppression: report of a pediatric patient with response to oral valganciclovir. Arch Dermatol (2010) 1.05
Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol (2012) 1.05
Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. J Natl Compr Canc Netw (2008) 1.04
In-vivo characterization of optical properties of pigmented skin lesions including melanoma using oblique incidence diffuse reflectance spectrometry. J Biomed Opt (2011) 1.04
Phase I/II randomized bilateral half-head comparison of topical bexarotene 1% gel for alopecia areata. J Am Acad Dermatol (2009) 1.03
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife (2013) 1.02
Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and NF-kappaB signaling. J Invest Dermatol (2010) 1.01
HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem (2012) 1.01
Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos (2004) 1.01
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr (2007) 1.01
Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics (2006) 1.00
Elevated virus loads of Kaposi's sarcoma-associated human herpesvirus 8 predict Kaposi's sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis (2002) 1.00
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res (2007) 0.99
Prediction of lung function response for populations exposed to a wide range of ozone conditions. Inhal Toxicol (2012) 0.98
High flotillin-2 expression is associated with lymph node metastasis and Breslow depth in melanoma. Melanoma Res (2006) 0.98
Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression. Cell Cycle (2014) 0.97
Adult Langerhans cell histiocytosis limited to the skin. Dermatology (2003) 0.97
Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol (2006) 0.97
Ozone exposure-response model for lung function changes: an alternate variability structure. Inhal Toxicol (2013) 0.97
Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol (2003) 0.96
Pediatric Sweet syndrome and immunodeficiency successfully treated with intravenous immunoglobulin. Pediatr Dermatol (2005) 0.96
Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol (2011) 0.96
Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Arch Dermatol (2004) 0.95
Skin scan: a demonstration of the need for FDA regulation of medical apps on iPhone. J Am Acad Dermatol (2013) 0.95
A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol (2012) 0.95
Concordance rate of alopecia areata in identical twins supports both genetic and environmental factors. J Am Acad Dermatol (2010) 0.95
Increased malignancy risk in the cutaneous T-cell lymphoma patient population. Clin Lymphoma Myeloma (2008) 0.95
Use of isotretinoin for acne vulgaris. Pediatr Ann (2009) 0.94
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol (2010) 0.94